Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mylan Joins Firms Facing DOJ Probe On Price Hikes; Senate Plans Industry-Free Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate Special Aging Committee hearing Wednesday to focus on price spikes in off-patent drugs without testimony from drug makers.


Related Content

Generic Industry Hit With Avalanche Of Price Fixing Suits
Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors
Could Drug Price Spikes Spur ANDA Priority Reviews?
Gilead's Pricing Strategy Faces New Opposition Tactics: Patent, Antitrust Suit
Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs
PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms


Related Companies